Author:
Pir Meryem,Ağırbaş Hikmet,Şahin Onur
Subject
Pulmonary and Respiratory Medicine,Pediatrics, Perinatology, and Child Health
Reference29 articles.
1. [1] Ciaravino V., Plattner J., Chanda S., An assessment of the genetic toxicology of novel boron-containing therapeutic agents, Environ. Mol. Mutagen., 54, 338−346, 2013.
2. [2] Campbell-Verduyn L. S., Bowes E. G., Li H., Vallee A. M., Vogels C. M., Decken A., Gray C. A., Westcott S. A., Heterocyclic aminoboron compounds as antituberculosis agents, Heteroat. Chem., 25 (2), 100−106, 2014.
3. [3] Ross J. E., Scangarella-Oman N., Jones R. N., Determination of disk diffusion and MIC quality control guidelines for GSK2251052: A novel boron-containing antibacterial, Diagn. Microbiol. Infec. Dis., 75, 437−439, 2013.
4. [4] Li X., Zhang Y. K., Plattner J. J., Mao W., Alley M. R. K., Xia Y., Hernandez V., et al. Synthesis and antibacterial evaluation of a novel tricyclic oxaborole-fused fluoroquinolone, Bioorg. Med. Chem. Lett., 23, 963−966, 2013.
5. [5] Li X., Zhang Y. K., Liu Y., Ding C. Z., Li Q., Zhou Y., Plattner J. J., et al. Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 protease, Bioorg. Med. Chem. Lett., 20 (12), 3550−3556, 2010.